CDC and FDA Recommendation to Pause Use of Johnson & Johnson COVID-19 Vaccine (Talking Points)
Resource Topic: Clinical Issues, Emerging Issues, Operations
Resource Subtopic: COVID-19, Emergency Management.
Year Developed: 2021
Resource Type: Publication
Primary Audience: Clinicians
Health Center Staff
Centers for Disease Control and Prevention
(See other resources developed by this organization).
In collaboration with
Food and Drug Administration.
Resource Summary: This resource provides talking points concerning the CDC and FDA's recommendation to pause the use of the Johnson & Johnson/Janssen COVID-19 vaccine after six reported U.S. cases of a rare and severe type of blood clot. The recommendation was made in order to prepare the health care system to recognize and treat patients appropriately.
Resource Details: As of April 12, more than 6.8 million doses of the Johnson & Johnson vaccine have been
administered in the U.S. CDC and FDA are reviewing data involving six reported U.S. cases of a
rare and severe type of blood clot in individuals after receiving the J&J vaccine. In these cases, a type of blood clot called cerebral venous sinus thrombosis (CVST) was seen in combination with low levels of blood platelets (thrombocytopenia). All six cases occurred among women between the ages of 18 and 48, and symptoms occurred 6 to 13 days after vaccination.